How to Cite
Abstract
The purpose of the study was to measure blood levels of insulin-like growth factors in patients with squamous cell carcinoma of the tongue and lower oral mucosa depending of the efficacy of cetuximab chemotherapy. The study included the data on 50 patients with squamous cell carcinoma of the tongue and lower oral mucosa T3-4N0-1M0. Patients received chemotherapy with cetuximab (n=30, main group) and without it (n=20, controls). Results were compared with the values in 20 non-cancer donors. Both groups of patients were divided into two subgroups: with stable disease and partial regression. Before treatment, blood serum levels of the two insulinlike growth factors IGF-1 and IGF-2 in patients were lower than in donors by 53.5% and 20.3%, respectively. A cycle of the standard chemotherapy in the subgroup with partial regression statistically significantly increased IGF-1 levels by 33% compared to the values before treatment, while IGF-2 was both within donor and initial values and the IGF-1/IGF- 2 ratio was similar to the initial level but 33% lower than in donors. Cetuximab chemotherapy in patients with partial regression normalized IGF-1 levels increasing it compared to initial values - by 87%. IGF-2 levels did not differ statistically significantly from their initial values and were 32.5% lower than in donors. The IGF-1/IGF-2 ratio was 58% higher than before treatment. Two therapy types demonstrated than cetuximab chemotherapy normalized IGF-1 in patients with partial tumor regression shown by the IGF-1 increase up to normal blood levels in effective treatment.
References
Esteller M. Epigenetics in cancer // N. Engl. J. Med. - 2008. - Vol. 13. - P. 1148-1159. - DOI: 10.1056/NEJMra072067
Foy J.P., Saintigny P., Goudot P., Schouman T., Bertolus C. The promising impact of molecular profiling on treatment strategies in oral cancers // J. Stomatol. Oral Maxillofac. Surg. - 2017. - Vol. 118. - P. 242-247. - DOI: 10.1016/j.jormas.2017.05.004
Irimie A.I., Ciocan C., Gulei D. et al. Current Insights into oral cancer epigenetics // Int. J. Mol. Sci. - 2018. - Vol. 19. - P. 670. - DOI: 10.3390/ijms19030670
Переводчикова Н.И. Таргетные препараты и их место в современной терапии опухолевых заболеваний // Клиническая гематология. - 2009. - Т 2. - №4. - С. 367-373.
Чучалин А.Г. Инновационные лекарственные средства XXI века // Вестник Российской Академии наук. - 2016. - Т. 86. - № 6. - С. 480-483.
Переводчикова Н.И., Горбунова В.А. Таргетные препараты и их клиническое использование: введение в проблему // Эффективная фармакотерапия в онкологии, гематологии и радиологии. - 2009. - № 2. - С. 6-13.
Льянова А.А., Владимирова Л.Ю., Франциянц Е.М., Кутилин Д.С. и др. Молекулярные механизмы основы современной таргетной терапии плоскоклеточного рака языка и слизистой дна полости рта моноклональными антителами // Злокачественные опухоли. - 2017. - Т. 7. - № 4. - С. 77-87.
Bonner J., Harari P., Giralt J. et al. Radiotherapy plus ce-tuximab for squamous-cell carcinoma of the head and neck // N. Eng. J. Med. - 2006. - Vol. 354. - P 567-578.
Pollack M. Insulin and insulin-like growth factor-like signaling in neoplasia // Nature Rev Cancer. - 2008. - Vol. 8. - P. 915-928.
Agieva A.A., Kit O.I., Frantsiyants E.M. et al. Role of epidermal growth factors and its soluble receptor in realization of anti- EGFR monoclonal antibodies effect in patients with head and neck cancer // Annals of Oncology. - 2016. - Vol. 27(6). - 995 р. - DOI: 10.1093/annonc/mdw376.47
Suzuki M., Ishikawa H., Tanaka A., Mataga I. Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue // Hum. Cell. - 2011. - Vol. 24. - P 21-29. - DOI: 10.1007/s13577-010-0004-x
De Groot S., Gelderblom H., Fiocco M. et al. Serum levels of IGF-1 and IGF-BP3 are associated with event-free survival in adult Ewing sarcoma patients treated with chemotherapy // Onco Targets Ther. - 2017. - Vol. 10. - P. 2963-2970. - DOI: 10.2147/0TT.S123726
Shao YY, Huang C.C., Lin S.D. et al. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antian-giogenic therapy // Clin Cancer Res. - 2012. - Vol. 18(14). - P 3992-3997.
Elmashad N., Ibrahim W.S., Mayah W.W. et al. Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma // Asian Pac. J. Cancer Prev. - 2015. - Vol. 16(2). - P. 613-619.
Kaseb A.O., Morris J.S., Hassan M.M. et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma // J. Clin. Oncol. - 2011. - Vol. 29(29). - P 3892-3899.
Tas F., Karabulut S., Bilgin E. et al. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer // Tumour Biol. - 2014. - Vol. 35(9). - P. 9303-9309.
Tas F., Karabulut S., Serilmez M. et al. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer // Tumour Biol. - 2014. - Vol. 35(4). - P. 3125-3132.
Cho E.J., Lee J.H., Yoo J.J. et al. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study // Clin Cancer Res. - 2013. - Vol. 19(15). - P 4218-4227.
Gallego R., Codony-Servat J., Garcia-Albeniz X. et al. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer // Endocr Relat Cancer. - 2009. - Vol. 16(1). - P. 311-317.
Huang YF., Cheng W.F., Wu YR et al. Circulating IGF system and treatment outcome in epithelial ovarian cancer // Endocr Relat Cancer. - 2014. - Vol. 21(2). - P. 217-229.
Schumacher B., Garinis G.A., Hoeijmakers J.H. Age to survive: DNA damage and aging // Trends Genet. - 2008. - Vol. 24(2). - P. 77-85.
Brady G., O'Regan E., Miller I. et al. Serum levels of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs), -1, -2, -3, in oral cancer // Int J Oral Maxillofac Surg. - 2007. - Vol. 36(3). - P. 259-262.
Bowers LW, Rossi EL, O>Flanagan CH, deGraffenried LA, Hursting SD. The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link // Front Endocrinol (Lausanne). - 2015. - Vol. 6. - P. 77. -. DOI: 10.3389/fen-do.2015.00077
Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins // Endocr Rev. - 2002. - Vol. 23. - P. 824-854.
Scartozzi M., Mandolesi A., Giampieri R. et al. Insulinlike growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan // Int J Cancer. - 2010. - Vol. 127(8). - P 1941-1947.
Gallego R., Codony-Servat J., Garcia-Albeniz X. et al. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer // Endocr Relat Cancer. - 2009. - Vol. 16(1). - P. 311-317.
Gallego R., Codony-Servat J., Garcia-Albeniz X. et al. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer // Endocr Relat Cancer. - 2009. - Vol. 16(1). - P. 311-317.
Kummel S., Eggemann H., Luftner D. et al. Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes // Int J Biol Markers. -2007. - Vol. 22(3). - P. 186-193.
Chung C.H., Pohlmann PR., Rothenberg M.L. et al. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma // Head Neck. - 2011. - Vol. 33 (12). - P. 1804-1808.
Brahmkhatri V. P., Prasanna, C., & Atreya, H. S. (2015). Insulin-like growth factor system in cancer: novel targeted therapies // BioMed research international. - 2015. - 538019. - DOI: 10.1155/2015/538019
Pollak M.N., Schernhammer E.S., Hankinson S.E. Insulin-like growth factors and neoplasia // Nature Reviews Cancer. - 2004. - Vol. 4(7). - P 505-518. - DOI: 10.1038/nrc1387
Eik Schiegnitz, Peer W Kammerer, Holger Schon, Christoph Gulle, Manfred Berres, Keyvan Sagheb, Bilal Al-Nawas. The matrix metalloproteinase and insulin-like growth factor system in oral cancer - a prospective clinical study // OncoTargets and Therapy. - 2017. - Vol. 10. - P 5099-5105.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019